Joint modeling of overall survival (OS) and tumor size for patient-level predictions of survival in non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Onishchenko, Dmitry [1 ]
Dunyak, James [2 ]
Masson, Eric [2 ]
Helmlinger, Gabriel [2 ]
Peskov, Kirill [1 ]
Tomkinson, Helen [4 ]
Stanski, Donald [3 ]
Al-Huniti, Nidal [2 ]
机构：
[1] M&S Decis LLC, Moscow, Russia
[2] AstraZeneca, IMED Biotech Unit, Quantitat Clin Pharmacol, Waltham, MA USA
[3] AstraZeneca, IMED Biotech Unit, Quantitat Clin Pharmacol, Gaithersburg, MD USA
[4] AstraZeneca, IMED Biotech Unit, Quantitat Clin Pharmacol, Cambridge, England
来源：
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS | 2017年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
W-091
引用
收藏
页码：S138 / S138
页数：1
相关论文
共 50 条
  • [31] The impact of alternative dosing regimens on overall survival (OS) in the treatment of non small cell lung cancer (NSCLC) with Erlotinib
    Pembroke, C.
    Pembroke, T.
    Vigneswaran, V.
    Rowley, K.
    [J]. LUNG CANCER, 2012, 75 : S10 - S10
  • [32] Treatment patterns, overall survival (OS), and disease-free survival (DFS) in early stage non-small cell lung cancer (NSCLC) following complete resection
    West, H.
    Hu, X.
    Burke, T.
    Walker, M. S.
    Wang, Y.
    Samkari, A.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S74 - S74
  • [33] Genetic polymorphisms correlate with overall survival (OS) in advanced non-small cell lung cancer (NSCLC) treated with carboplatin (CBDCA) and paclitaxel (PTX)
    Yamamoto, N.
    Sato, Y.
    Tamura, T.
    Kunitoh, H.
    Ohe, Y.
    Katori, N.
    Sawada, J.
    Sekine, A.
    Nakamura, Y.
    Saijo, N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [34] Prognostic Factors for Overall Survival among Patients with Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Verleger, Katharina
    Treur, Maarten
    Penrod, John
    Daumont, Melinda
    Lees, Michael
    Macahilig, Cynthia
    Solem, Caitlyn
    Jiang, Shan
    Chirita, Oana
    Hertel, Nadine
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S995 - S996
  • [35] Trends in drug costs and overall survival in patients diagnosed with metastatic non-small cell lung cancer (NSCLC)
    Cramer-van der Welle, Christine
    Peters, Bas J. M.
    Deenen, Maarten J.
    Schramel, Franz M. N. H.
    Van de Garde, Ewoudt M. W.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [36] Association of PAK4 expression with overall survival in patients with non-small cell lung cancer (NSCLC).
    Mamdani, Hirva
    Wu, Sharon
    Morgan, Erin
    Khan, Husain Yar
    Nabhan, Chadi
    Nieva, Jorge J.
    Korn, Wolfgang Michael
    Uprety, Dipesh
    Puri, Sonam
    Khan, Hina
    Raez, Luis E.
    Borghaei, Hossein
    Halmos, Balasz
    Ma, Patrick C.
    Lopes, Gilberto
    Liu, Stephen V.
    Azmi, Asfar S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [37] SURVIVAL OF PATIENTS WITH BRAIN METASTASES AND NON-SMALL CELL LUNG CANCER (NSCLC)
    Randhawa, J. K.
    Patel, S. P.
    Stokes, T. C.
    [J]. THORAX, 2009, 64 : A148 - A148
  • [38] Association between baseline tumor dimensions and survival in advanced non-small cell lung cancer (NSCLC)
    Ahn, Daniel H.
    Dahlberg, Suzanne Eleanor
    Sandler, Alan
    Perry, Michael C.
    Schiller, Joan H.
    Brahmer, Julie R.
    Johnson, David H.
    Gerber, David E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [39] Senescence signature affects overall survival in non-small cell lung cancer
    Domen, A.
    Deben, C.
    Hermans, C.
    Lambrechts, H.
    Siozopoulou, V.
    Pauwels, P.
    Van De Wiel, M.
    Janssens, A.
    Hendriks, J. M. H.
    van Schil, P. E.
    Vandamme, T.
    Prenen, H.
    Peeters, M.
    Lardon, F.
    Wouters, A.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S943 - S943
  • [40] Spirometry at diagnosis and overall survival in non-small cell lung cancer patients
    Zhai, Ting
    Li, Yi
    Brown, Robert
    Lanuti, Michael
    Gainor, Justin F.
    Christiani, David C.
    [J]. CANCER MEDICINE, 2022, 11 (24): : 4796 - 4805
12345